MiRus

Executive Summary

MiRus is a U.S.-based medical device company pioneering the use of its proprietary MoRe® (Molybdenum-Rhenium) superalloy to create safer and more durable implants for cardiovascular and orthopedic applications. Founded in 2007 and headquartered in Marietta, Georgia, the company offers an integrated platform covering pre-operative, intra-operative, and post-operative solutions, including advanced implant designs, procedural approaches, and remote monitoring systems. Focus areas include structural heart, spine, extremity, and procedural solutions. By leveraging the unique properties of the MoRe alloy—such as high strength, fatigue resistance, and MRI compatibility—MiRus aims to address limitations of traditional implant materials and improve patient outcomes. The company is privately held and has not disclosed total funding or valuation, but its technology has potential to disrupt the medical implant market. MiRus' ability to scale manufacturing and secure regulatory clearances will be key to its success.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation spine implant70% success
• Q4 2026Partnership or distribution agreement for structural heart devices50% success
• Q2 2026Publication of clinical data on MoRe alloy extremity implants60% success